Incyte recently announced that its innovative drug Zynyz® (Retifanlimab) has been approved by the European Commission as a first-line treatment for advanced squamous cell anal carcinoma (SCAC).
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
TotalEnergies says Iran war could accelerate energy transition
New Token Issuance for This Altcoin Could Drop by 36 Percent: Critical Vote Passes
US October ISM Manufacturing Index Expands Beyond Expectations, Output Growth Hits Strongest Level in Nearly Five Years
The Manufacturing Purchasing Managers' Index (PMI) released by the Institute for Supply Management (ISM) in the United States rose by 1 point in October to reach 55.5, marking the second highest reading in more than four years and exceeding the market expectation of 54.7. The production index recorded its best performance since the end of 2021, while the new orders index, a key indicator of demand, also reached its highest level since July.
Crypto prices
More
